During pregnancy, pregnant women are susceptible to malaria, contributing significantly to maternal and infant mortality. Over the past 100 years, several treatments for malaria have been proposed, but have systematically failed, largely due to the emergence of drug resistance, in part due to exposure of the parasite to low doses of the drug. Moreover only few anti malaria drug can be used for pregnant malaria. Streptomyces hygroscopicus subsp Hygroscopicus is a potential source for bioactive molecules that produce secondary metabolites that could be served as antimalarial agents. Aim: This research was conducted to study the effect of secondary metabolite extract of Streptomyces hygroscopicus subsp Hygroscopicus on fetal growth and placental cell VEGF expression in pregnant mice. Methods: An experimental study had conducted using Swiss mice infected with P. berghei as a malaria pregnancy model. Samples were divided into 3 control groups, there were (i) normal mice without any treatment or K- group (ii) normal mice treated with Streptomyces hygroscopicus extract dose 2600 μg/kgBW or KP group (iii) infected mice with P. berghei or K+ group, and 5 treatment groups there were (iv) mice infected with P. berghei and treated intra-peritoneal with Artemisinin or PA group, and mice infected with P. berghei and treated with metabolite extract of S. hygroscopicus (v) dose of 1600 μg/kgBW or P1 group, (vi) dose of 2600 μg/kgBW or P2 group, (vii) dose of 3600 μg/kgBW or P3group and the last (vii) dose of 4600 μg/kgBW or P4 group for 5 days respectively. The degree of parasitemia was measured from the first day of malaria induction until the last treatment. On day 15th of post mating, all of the pregnant mice were sacrificed. Fetal weights were measured using analytic balance. Expression of VEGF expression in the placental tissue was measured using immunohistochemistry.